Ajax Therapeutics CEO Martin Vogelbaum (L) and co-founder Ross Levine

'At­tack JAK': Ajax se­cures $95M to test new JAK2 in­hibitor af­ter in­dus­try's string of myelofi­bro­sis deals

A large phar­ma com­pa­ny want­ed to buy Ajax Ther­a­peu­tics when it was rais­ing a $40 mil­lion Se­ries B in 2021. But the start­up thought it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.